- Previous Close
0.0107 - Open
0.0109 - Bid --
- Ask --
- Day's Range
0.0101 - 0.0109 - 52 Week Range
0.0101 - 0.0109 - Volume
35,380 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 2.27
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
www.conduitpharma.comRecent News: CDTTW
View MoreCompare To: CDTTW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDTTW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-168.82%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.8M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
554k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.45M